{
    "root": "e77bac85-1241-4be2-89d9-3af4d939dc1b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Bupropion Hydrochloride",
        "suffix": {
            "text": "XL"
        }
    },
    "value": "20250311",
    "ingredients": [
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        },
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL 1450",
            "code": "OJ4Z5Z32L4"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": "bupropion hydrochloride extended-release tablets ( xl ) aminoketone antidepressant , indicated : \u2022 treatment major de pressive disorder ( mdd ) ( 1.1 ) \u2022 prevention seasonal affective disorder ( sad ) ( 1.2 )",
    "contraindications": "general : \u2022 increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) \u2022 periodically reassess dose need maintenance treatment . ( 2.2 ) major depressive disorder \u2022 starting dose : 150 mg daily . usual target dose : 300 mg daily ( 2.2 ) \u2022 4 days , may increase dose 300 mg daily . ( 2.2 ) seasonal affective disorder \u2022 initiate treatment autumn prior onset seasonal depressive symptoms . ( 2.3 ) \u2022 starting dose : 150 mg daily . usual target dose : 300 mg daily . ( 2.3 ) \u2022 one week , may increase dose 300 mg daily . ( 2.3 ) \u2022 continue treatment winter season . ( 2.3 ) hepatic impairment \u2022 moderate severe hepatic impairment : 150 mg every day ( 2.6 ) \u2022 mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.6 , 8.7 ) renal impairment \u2022 consider reducing dose and/or frequency dosing . ( 2.7 , 8.6 )",
    "warningsAndPrecautions": "bupropion hydrochloride extended-release tablets usp ( xl ) , 150 mg bupropion hydrochloride , white pale yellow , round biconvex tablet imprinting \u201c yh 102 \u201d cartons 30 tablets ( 10 tablets blister pack x 3 ) , ndc 0904-7084-04 cartons 100 tablets ( 10 tablets blister pack x 10 ) , ndc 0904-7084-61 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp child-resistant closure . keep reach children . bupropion hydrochloride extended-release tablets usp ( xl ) may odor .",
    "adverseReactions": "\u2022bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients seizure disorder . \u2022bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated bupropion hydrochloride extended-release tablets ( xl ) [ ( 5.3 ) ] . \u2022bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) ( 7.3 ) ] . \u2022the maois ( intended treat psychiatric disorders ) concomitantly bupropion hydrochloride extended-release tablets ( xl ) within 14 days discontinuing treatment bupropion hydrochloride extended-release tablets ( xl ) contraindicated . increased risk hypertensive bupropion hydrochloride extended-release tablets ( xl ) used concomitantly maois . bupropion hydrochloride extended-release tablets ( xl ) within 14 days discontinuing treatment maoi also contraindicated . starting bupropion hydrochloride extended-release tablets ( xl ) patient treated reversible maois linezolid intravenous methylene blue contraindicated [ ( 2.9 ) , ( 5.4 ) ( 7.6 ) ] . \u2022bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients known hypersensitivity bupropion ingredients bupropion hydrochloride extended-release tablets ( xl ) . anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "indications_original": "Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: \u2022 treatment of major de pressive disorder (MDD) ( 1.1 ) \u2022 prevention of seasonal affective disorder (SAD) ( 1.2 )",
    "contraindications_original": "General: \u2022 Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) \u2022 Periodically reassess the dose and need for maintenance treatment. ( 2.2 ) Major Depressive Disorder \u2022 Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily ( 2.2 ) \u2022 After 4 days, may increase the dose to 300 mg once daily. ( 2.2 ) Seasonal Affective Disorder \u2022 Initiate treatment in the autumn prior to onset of seasonal depressive symptoms. ( 2.3 ) \u2022 Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily. ( 2.3 ) \u2022 After one week, may increase the dose to 300 mg once daily. ( 2.3 ) \u2022 Continue treatment through the winter season. ( 2.3 ) Hepatic Impairment \u2022 Moderate to severe hepatic impairment: 150 mg every other day ( 2.6 ) \u2022 Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.6 , 8.7 ) Renal Impairment \u2022 Consider reducing the dose and/or frequency of dosing. ( 2.7 , 8.6 )",
    "warningsAndPrecautions_original": "Bupropion Hydrochloride Extended-Release Tablets USP (XL), 150 mg of bupropion hydrochloride, are white to pale yellow, round biconvex tablet with imprinting \u201cYH 102\u201d in \n                  Cartons of 30 tablets (10 tablets each blister pack x 3), NDC 0904-7084-04\u00a0\n                  Cartons of 100 tablets (10 tablets each blister pack x 10), NDC 0904-7084-61\n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure.\n                  \n                  \n                     Keep out of reach of children.\n                  \n                  Bupropion Hydrochloride Extended-Release Tablets USP (XL) may have an odor.",
    "adverseReactions_original": "\u2022Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.\n                     \n                        \u2022Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL)                                 [see                                       Warnings and Precautions (5.3)].                                 \n                     \n                     \n                        \u2022Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs                                  [see                                       Warnings and Precautions (5.3) and                                       Drug Interactions (7.3)].                                 \n                     \n                     \n                        \u2022The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated                                 [see                                       Dosage and Administration (2.9),                                       Warnings and Precautions (5.4) and                                       Drug Interactions (7.6)].                                 \n                     \n                     \n                        \u2022Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported                                 [see                                       Warnings and Precautions (5.8)]."
}